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Abstract
Background: Psychomotor agitation (PMA) is a state of motor restlessness and mental tension that requires prompt
recognition, appropriate assessment and management to minimize anxiety for the patient and reduce the risk for
escalation to aggression and violence. Standardized and applicable protocols and algorithms can assist healthcare
providers to identify patients at risk of PMA, achieve timely diagnosis and implement minimally invasive management
strategies to ensure patient and staff safety and resolution of the episode.
Methods: Spanish experts in PMA from different disciplines (psychiatrists, psychologists and nurses) convened in Barcelona
for a meeting in April 2016. Based on recently issued international consensus guidelines on the standard of
care for psychiatric patients with PMA, the meeting provided the opportunity to address the complexities in
the assessment and management of PMA from different perspectives. The attendees worked towards producing a
consensus for a unified approach to PMA according to the local standards of care and current local legislations. The
draft protocol developed was reviewed and ratified by all members of the panel prior to its presentation to the Catalan
Society of Psychiatry and Mental Health, the Spanish Society of Biological Psychiatry (SEPB) and the Spanish Network
Centre for Research in Mental Health (CIBERSAM) for input. The final protocol and algorithms were then submitted to
these organizations for endorsement.
Results: The protocol presented here provides guidance on the appropriate selection and use of pharmacological
agents (inhaled/oral/IM), seclusion, and physical restraint for psychiatric patients suspected of or presenting with PMA.
The protocol is applicable within the Spanish healthcare system. Implementation of the protocol and the constituent
algorithms described here should ensure the best standard of care of patients at risk of PMA. Episodes of PMA could
be identified earlier in their clinical course and patients could be managed in the least invasive and coercive manner,
ensuring their own safety and that of others around them.
Conclusion: Establishing specialized teams in agitation and providing them with continued training on the identification
of agitation, patient management and therapeutic alternatives might reduce the burden of PMA for both the patient and
the healthcare system.
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Background
Psychomotor agitation (PMA), a state of motor restless-
ness and mental tension, is associated with a variety of
psychiatric conditions [1]. PMA may be evidenced by an
increased motor activity (e.g. excessive gesturing) and
emotional activation but may also be accompanied by
emotional lability and a decreased level of attention and
alterations in cognitive function. PMA is particularly
prevalent in among the schizophrenia and bipolar disorder
(BD) population [2]. In Spain, a recent report indicated
that 25% of patients with schizophrenia and 15% of those
with BD could be expected to suffer at least one episode
of PMA each year, with a median of 2 episodes per year
per patient [3].
Emergent PMA requires timely recognition, appropriate
assessment and management to minimize anxiety for the
patient and reduce the risk for escalation to aggression
and violence that may be directed towards themselves or
others [2]. Episodes of PMA may be encountered in the
context of inpatient psychiatric care facilities but also in
the emergency room setting and in outpatient clinics [2].
Recent studies suggest that up to 10% of all emergency
psychiatric interventions are related to PMA [4–6]. Con-
sequently, an adequate identification and management of
PMA is an essential component of the care of patients
with psychiatric disorders [7].
As agitation is understood as a continuum of symptoms
ranging from mild to severe, [8] it is essential to detect
episodes of PMA in their earliest manifestation to avoid a
possible escalation of symptoms. Ineffective management
of PMA might result in the unnecessary use of coercive
measures (involuntary medication, physical restraint, and
seclusion) that could potentially precipitate aggression or
violence [9]. Moreover delayed and/or inappropriate
management of PMA might lead to an increased use of
hospital resources and avoidable hospitalizations with
significant economic costs.
International expert consensus recommendations have
been recently published for the assessment and manage-
ment of patients with PMA due to their primary psychiatric
condition [2]. However, there is a lack of standardized pro-
tocols and clinical tools to assist clinicians and healthcare
professionals (HCP) in achieving the best possible outcome
for patients presenting with an episode of PMA.
Against this background, we aimed to elaborate a protocol
developed for the assessment and management of patients
with PMA. The key difference with the original consensus
article [2] is that it was a broad compilation of all the avail-
able bibliography on the topic that may not be always easy
to apply to the daily clinical practice. Medical protocols
have to be based on the current and high degree evidence
literature; however, an adequate and adapted guidance to
all health care systems is not always achieved from the lit-
erature perspective. Because of that, despite the current
protocol is based on the same information of a recent crit-
ical review of the literature [2], it is aimed to provide
specific guidance for the care of patients presented with
an agitation episode adapted and specified not only to be
close to clinical practice but also to be in accordance to
the Spanish health care system. When used in the clinical
setting, this protocol will reduce the anxiety of the patient,
ensure physical safety of both patient and HCPs and
minimize the risk for escalation to aggressive behaviour
and violence by means of a series of standardized actions.
Methods
This protocol represents an application and adaptation of
recently published international consensus guidelines on
the management of psychiatric patients with PMA [2].
The methodology consisted in a search of the most
relevant articles [2], a systematic review according to the
Jadad scale [10] and according to the PRISMA statement
criteria [11], and a consensus among different inter-
national experts on the topic of PMA using the Delphi
methodology [12]. After this international consensus
was presented, main authors (EV, MG) decided to lead a
new specific panel of experts in their own country to
seek applicability of this protocol according to the Spanish
mental health policies and laws. Using these guidelines as a
foundation and the internal Standard Operating Procedures
(SOP) from the Hospital Clínic i Provincial de Barcelona, a
panel of Spanish mental health professionals with relevant
experience in clinical guideline development and/or in sys-
tematic reviews research methodology was then convened.
The expert committee consisted of eight psychiatrists, two
nurses and one psychologist who were organized into
subpanels based on their expertise. The purpose of the
panel was to provide expert advice during the development
process. A core group (EV, MG, LC) was established to
design the protocol and provide more time-sensitive and
operational advice according to the local policies and
national laws. The core group also developed a multistep
process that included an assessment of existing updated
clinical guidelines, semi structured interviews, a Delphi
internal consensus survey, and an external review with
official national mental health scientific societies. A first
round of possible evaluation and treatment recommenda-
tions, the evidence upon which they were based and the
adequacy of their implementation in the Spanish healthcare
system, were reviewed at a meeting of the expert panel in
April 2016. Subsequently, draft recommendations were pre-
pared by the subpanels which were then circulated to the
entire group for consensus through semi structured inter-
views and Delphi consensus throughout 2016. Once
preliminary recommendations were agreed by the expert
panel, an external review was requested to the Catalan
Society of Psychiatry and Mental Health as well as the
Spanish Society of Biological Psychiatry (SEPB) and the
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Spanish Network Centre for Research in Mental Health
(CIBERSAM) for input and endorsement of the recom-
mendations included in the protocol.
The final protocol is presented in three main sections,
the first section covers the initial identification and evalu-
ation of a patient presenting with or suspected of PMA
including assessment tools and differential diagnosis guid-
ance. The second section covers recommendations for
selection of appropriate interventions during an episode
of PMA including environmental modifications, verbal
de-escalation, pharmacological treatment and physical re-
straint. The third section details evaluations that should
be undertaken following an episode of PMA. In addition
to these main sections, three clinical algorithms have been
developed to provide easy and quick guidance on the main
recommendations of the protocol in relation to the initial
and general management of the patient with PMA, the se-
lection of appropriate pharmacological interventions, and
standards of care when physical restraint is needed.
Results
Protocol 1: Identification and evaluation of psychomotor
agitation
When PMA is suspected, it is recommended that the
first step in the evaluation of these patients should be to
ensure they are safe [2]. This may involve moving them
to a safe environment where the risk to themselves or
others are minimized and a prompt evaluation of their
current clinical state and the risk for an escalation of
their symptoms can be undertaken. The initial evalu-
ation should include consideration of the presence of
risk factors for PMA, these may include demographic
factors (males, less than 40 years old, low educational
level, etc.), psychosocial factors (history of conflict with
staff or other patients, a recent stressful life event, involun-
tary or long-term admission, etc.) or clinical factors (per-
sonal or family history of previous agitation episodes,
anxiety, fear, substance use, low adherence to treatment,
etc.). Several rating scales are available that can be used to
evaluate the future risk of agitation, aggression and associ-
ated violence in psychiatric inpatient settings. These include
the Broset Violence Checklist (BVC [13]), the Historical
Clinical Risk Management – 20 (HCR-20 [14]) and the
McNiel-Binder Violence Screening Checklist (VSC [15]).
Figure 1 provides an algorithm for the initial evaluation
and management of the patient with PMA. The initial
assessment should be made by two HCPs with experience
in the assessment and management of patients with PMA.
The aim of the initial assessment is to (1) exclude poten-
tial medical causes, (2) achieve rapid stabilization of the
patient’s condition, (3) avoid the use of coercive measures,
(4) ensure the least restrictive form of management, (5)
achieve a therapeutic alliance with the patient and (6)
develop an appropriate care plan [2, 8].
The signs and symptoms that may help in the identifica-
tion of a PMA are shown in Table 1. PMA is a clinical
phenomenon whose severity is presented as a continuum
and so its signs and symptoms. To measure the symptom
escalation and severity of agitation, several rating scales
have been developed, including the Clinical Global
Impression Scale for Aggression (CGI-A; [16]), the
Positive and Negative Syndrome Scale – Excited Compo-
nents (PANSS-EC or PEC; [17]) and the Behavioural Activ-
ity Rating Scale (BARS; [18]). The CGI-A relies only on the
judgement of the physician and patients can be rapidly eval-
uated for the severity of their aggressive symptoms using a
5-point Likert scale (1 indicates aggressive behaviour is not
present and 5 represents aggressive behaviour is present).
The PANSS-EC evaluates 5 items on a scale of 1 to 7
and represents a simple intuitive tool for the evaluation
agitated psychiatric patients. Unlike the CGI-A and the
PANSS-EC, the BARS measures the severity of agitate
behaviour using a single item consisting of 7 levels of
severity from a state of sedation to one of agitation.
This scale is rapid and easy to administer and does not
require medical training.
In addition to the immediate evaluation of the patient’s
current state, a medical, toxicological, psychiatric and
pharmacological history should be reviewed. Events
leading up to the presentation for care should also be
considered to identify possible precipitating factors for the
current episode of PMA. Physical examination should be
undertaken including vital signs, glucose levels, blood
oxygen saturation, hepatic and renal function and urine
drug test [2]. Electrocardiogram, X-ray of the thorax,
lumbar puncture and pregnancy test for females may
also be considered [2].
Establishing a differential diagnosis
A correct differential diagnosis will help identify the pos-
sible underlying cause of the episode of PMA and facilitate
the identification of an appropriate management strategy. If
the patient’s status does not allow differential diagnosis, a
medical condition should be assumed until proven other-
wise [2]. PMA due to medical causes typically presents with
an acute or subacute onset, frequently in patients of
advanced age, without prior psychiatric history and follows
a fluctuating course. Such patients tend to exhibit an al-
tered level of consciousness, temporal-spatial disorientation
and alteration in physical parameters (sweating, tachycar-
dia, tachypnoea, fever, etc.). Visual hallucinations and delu-
sional ideation as well as cognitive impairment may also be
apparent. Due to this, the presence of a confusional state,
cognitive impairment, and intoxication/withdrawal syn-
drome from substances should be considered before con-
sidering a psychiatric disorder, especially in cases without
past psychiatric history. PMA due to psychiatric causes has
generally an acute or subacute onset and presents without
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alterations in the level of consciousness. If the patient pre-
sents with prior psychiatric history, PMA tends to appear
in the context of an acute relapse of their mental health
disorder. To facilitate a proper management, it has been
recommended to differentiate psychotic PMA (associated
with schizophrenia, BD) from non-psychotic PMA (associ-
ated with anxiety disorders, affective disorders, personality
disorders, mental retardation, autism spectrum disorders or
adjustment disorders).
If agitation due to medical cause of intoxication/with-
drawal syndrome from substances is suspected, supple-
mental examinations should be requested and the case
should be handled in a General Medicine Emergency
Department. If the agitation is due to a psychiatric cause,
the patient should be treated in a Psychiatric Emergency
Department, if it exists at the centre. If the hospital does
not have a Psychiatric Emergency Department, the patient
should be assisted in the General Medicine Emergency
Department.
Fig. 1 Algorithm for action in agitation. Algorithm for the initial identification and first steps in the management of the patient with psychomotor agitation
Table 1 Signs and symptoms of psychomotor agitation [2]
Type Signs and Symptoms
Changes in behaviour • Combative attitude
• Inappropriate behaviour without clear purpose
• Hyperreactivity to stimuli
• Inability to remain quiet, seated or calm
• Exaggerated gesticulation
• Facial tension and angry expression
• Defiant and/or prolonged visual contact
• Raised tone of voice, silence or refusal to
communicate
• Altered emotional state with appearance
of anxiety, irritability or hostility
• Verbal and/or physical aggression against
self or others or objects
Cognitive changes • Fluctuations in the levels of consciousness
• Temporo-spatial disorientations
• Tendency to frustration
• Difficulty in anticipating consequences
• Delusional ideas and/or hallucinations
Change in physical
parameters
• Fever
• Tachycardia
• Tachypnoea
• Sweating
• Tremor
• Neurological signs such as difficulty walking
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Protocol 2: Interventions during an episode of psychomotor
agitation
The objectives of an effective management of the PMA,
as defined by Zeller and co-workers [8] are to: stabilise
the patient quickly; avoid coercive measures; treat in the
least restrictive manner; form a therapeutic alliance; and
ensure an adequate plan for subsequent care.
Initial interventions should be always attempted in the
least restrictive manner: environmental modifications
and verbal de-escalation. Then, depending of the severity
of the PMA, these techniques might be supplemented by
more restrictive options that include pharmacological
treatment and/or physical restrain if needed.
Environmental modifications
These strategies may be useful to prevent an episode of
PMA, to treat an episode during the early stage and to
minimize a possible escalation of symptoms [2]. Environ-
mental modifications aim to ensure physical comfort of the
patient and reduce external stimuli (irritating factors such
as light, noise, cold or hot air currents). Removal of all
objects that may be potentially dangerous and maintenance
of an optimal safe distance to respect the patient’s personal
space should also be undertaken.
Verbal de-escalation
This interactive and complex technique is a dynamic
process in which the patient is oriented towards a state
of calm meanwhile the therapeutic relationship is estab-
lished [19]. Verbal de-escalation has been shown to reduce
PMA and the risk of symptoms escalation as well as to
reduce the need for coercive measures [8]. The objectives
of verbal de-escalation are: to re-establish patient’s self-
control; introduce clear behavioural limits; ensure the
safety of the patient, staff, and other users of the health-
care system; achieve a therapeutic alliance with the patient
that permits performance of an appropriate diagnostic
evaluation; ensure involvement of the patient in his/her
own therapeutic decision-making process; and reduce
hostility and aggressiveness, preventing possible episodes
of violence [8, 19]. While a team approach is needed to
manage the patient with PMA, it is recommended that
only one person interacts directly with the patient when
verbal de-escalation is attempted [19]. This interaction
should be calm and concise using simple language, active
listening and repetition to establish trust and to identify
the patient’s feelings and needs [8]. Table 2 outlines the
essential component of a verbal de-escalation technique.
Pharmacological treatment
The primary goal of pharmacological treatment is to
rapidly calm the patient without over sedation. Throughout
the process, both verbal de-escalation and environmental
modification techniques should be maintained.
Figure 2 provides an algorithm for the selection of
appropriate pharmacological agents guided by the under-
lying cause and severity of the agitation. All HCPs should
be familiar with the available treatments and well trained
on when and how to use the different alternatives in order
to choose the most convenient one in each case. Ideally,
the route of administration should be non-invasive and
non-traumatic, to preserve the physician-patient partner-
ship, and the patient should be involved in the decision-
making process. Where possible, medication should be
given as monotherapy. A rapid onset of action is also a
desirable feature of an ideal medication for the treatment
of acute PMA.
In case of psychiatric agitation, the preferred pharmaco-
logical treatment option if agitation is due to psychotic
symptoms is antipsychotic agents although benzodiazepines
may also be considered when agitation is due to a non-
psychotic agitation [8, 20]. In cases where a rapid effect of
the antipsychotic medication is needed, and the patient
cooperates, consider a medication with an inhaled route of
administration (loxapine; [21, 22]) or an oral/sublingual for-
mulation (olanzapine, risperidone, asenapine, aripiprazole,
quetiapine, ziprasidone or haloperidol). Intramuscular (IM)
antipsychotic agents (haloperidol, olanzapine [23], ziprasi-
done [24], aripiprazole [25, 26] and levomepromazine) may
Table 2 Essential elements of a verbal de-escalation technique [20]
• Talk with the patient in a gentle, relaxed, assured tone
• Answer calmly, maintaining a firm attitude
• Offer food, beverages and blankets
• Be flexible in the dialogue
• Reserve your own judgement regarding what the patient should or
should not do
• Do not seek confrontation of ideas or reasons, only simple
partnerships that calm and reinforce the patient
• Use simple language and short sentences, repeating as many times
as necessary
• Be honest and accurate
• Clearly communicate that the patient is expected to maintain self-
control and that the staff can help him/her achieve this
• Redirect the conversation when disruptive questions are asked
• Paraphrase what the patient says
• Reassure the patient that you have understood him/her well
• Use open-ended questions
• Establish limits whilst at the same time offering the patient
acceptable and realistic opportunities to improve their symptoms
• When faced with imminent violence:
• Warn the patient that violence is not acceptable
• Propose a resolution to any problem through dialogue
• Offer pharmacological treatment
• Inform them that you will rely on physical restraint if necessary
• Consider a mild/moderate show of force in the form of an increased
number of medical staff and even security guards ready to act if
necessary
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be considered for patients who refuse to cooperate with an
inhaled or orally administered medication. Despite antipsy-
chotics have been widely used in treating PMA, it has to be
noted that some are not indicated for PMA itself but for
the possible psychiatric underlined condition (e.g.; oral
formulations for olanzapine, risperidone, asenapine, aripi-
prazole, quetiapine, ziprasone and haloperidol, and the IM
formulations of haloperidol and levomepromazine [20]).
Table 3 provides an overview of the pharmacological treat-
ment options (approved and not currently approved) for
the psychiatric patient presenting with PMA and their suit-
ability with regard to the underlying cause of the PMA.
Caution should be exercised when diagnostic aetiology
is not sufficiently clear (undifferentiated agitation) and
the patient presents with an altered state of consciousness,
in this situation a medical condition for the PMA should be
considered until demonstrated to be the contrary [2]. In
this regard, both PMA due to medical condition or undif-
ferentiated agitation, should be initially treated with anti-
psychotic agents. For agitation in patients with Parkinson’s
or Parkinson’s-like disorder, the typical antipsychotics (halo-
peridol, levomepromazine) should be avoided and ziprasi-
done can be considered as an alternative [2]. For postictal
agitation, it may be advisable to use benzodiazepines [2].
When the likely cause of the PMA is related to alcohol
and/or benzodiazepine intoxication, caution should be
exercised regarding the use of sedatives due to the risk
of respiratory depression [2]. Antipsychotics should be
considered to avoid the risk of arterial hypertension and
respiratory depression. In cases of alcohol and/or benzodi-
azepine withdrawal, a benzodiazepine should be consid-
ered to reduce the risk of seizures and delirium tremens
[2]. In addition, adding B-vitamin treatment in these
patients might also prevent serious complications in
alcohol user patients [27]. For cases of cocaine and synthetic
drug intoxication, initial sedation with benzodiazepine
should be considered instead of antipsychotics in order
to decrease the potential risk of seizures [2].
Seclusion and physical restraint
Under special circumstances and as a last resource to
control de patient, for non-collaborative patients with
severe PMA, it might be necessary the use of seclusion
and physical restraint to ensure the safety of the patient
and the staff and to guarantee pharmacological treatment.
These treatment approaches always must be chosen as a
last resort treatment. When seclusion is needed, a specially
equipped room should be used for seclusion with protective
walls and equipped doors to guarantee the reduction of
stimuli and the safety of the patient.
Physical restraint is a procedure during which approved
mechanical holding devices are used to limit the patient’s
physical mobility [3]. Physical restraint is indicated in
patients exhibiting risky behaviour towards themselves or
Fig. 2 Algorithm for choice of medication. Algorithm for the selection of appropriate pharmacological intervention for the patient with
psychomotor agitation
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those around them, with agitation that cannot be con-
trolled pharmacologically and/or who require temporary
restraint to receive the appropriate treatment. Physical
restraint should be considered as exceptional and a last
recourse when other strategies have failed as this approach
could result in negative outcomes for the patient (includ-
ing physical and mental health negative effects). From the
beginning of this process, the patient must be informed
about the reason for the restraint, and given a further
opportunity to comply with alternative treatment options.
It should be explained that the restraint is not a punish-
ment but is intended to ensure their safety.
Physical restraint is a measure limiting the individual’s
freedom and, therefore, must be authorized by the patient
or the appropriate local authority. In relation to the current
Spanish local policies, the physical restraint may be applied
as follows:
 Patient admitted voluntarily and with consent for
immobilisation: restraint is voluntary or requested
by the patient in the event of failure of other
measures. Despite this, since they are deprived of
liberty, this must be communicated to the local
authorities.
 Patient admitted voluntarily but without consent for
immobilisation: physical restraint is applied against
their will and, although under voluntary admission,
it would then be considered involuntary and the
local authorities must be informed.
 Patient with involuntary admission: physical restraint is
applied against their will in an involuntary admission,
where the local authorities have been already awarded
of this admission.
The previous clinical status of the patient must be taken
into consideration when physical restraint is applied. Situa-
tions in which the use of physical restraint is contraindi-
cated include recent eye surgery or neurosurgery, which
may result in increased intraocular or intracranial pressure.
Figure 3 provides an algorithm for the best standards of
care and monitoring when physical restraint is needed.
Once the decision has been made that physical restraint is
required and appropriate (not contra-indicated), staff
should remove not only all potentially harmful objects
from their person but also any objects that the patient is
carrying. The bed must have approved restraint materials
and should be at the lowest level possible. No further
attempts at verbal de-escalation should be undertaken
during the development of the technique. The patient
and/or their family should be informed and consent re-
quested although non-consent by the patient does not
preclude the application of physical restraint. A single
member of staff should communicate with the patient and
coordinate the restraint team. If the patient cooperates,
Table 3 Pharmacological treatment options for the patient presenting with psychomotor agitation [21]
Route of administration Agent Dose Cause of agitation
Antipsychotics
Inhaled Loxapine 9.1 mg Psychotic syndrome (schizophrenia, bipolar disorder)
Oral Olanzapine 5–10 mg Undifferentiated agitation
Medical illness (cognitive deterioration and confusion syndrome)
Substance intoxication/abstinence
Psychiatric illness (schizophrenia, bipolar disorder, mental retardation
and autism spectrum disorder)
Risperidone 1–3 mg
Asenapine 5–10 mg
Aripiprazole 15–30 mg
Quetiapine 50–100 mg
Ziprasidone 20–40 mg
Haloperidol 5 mg
Intramuscular Haloperidol 5–15 mg
Olanazapine 5–10 mg
Ziprasidone 10 mg
Aripiprazole 9.75 mg
Levomepromazine 25 mg
Benzodiazepines
Oral Diazepam 5–10 mg Abstinence from alcohol and/or BZD
Psychiatric illness (anxiety disorder, affective disorder, personality and
adjustment disorder)Clonazepam 1–2 mg
Lorazepam 1 mg
Intramuscular Midazolam 5 mg
Diazepam 5–10 mg
BZD, benzodiazepine
Vieta et al. BMC Psychiatry  (2017) 17:328 Page 7 of 11
they should be escorted to the bed by two personnel hold-
ing the patient at the armpit and wrist. Five personnel are
required for a non-cooperative patient. They should be
guided to the floor and supported by the shoulders and
forearms, legs, knees and ankles during transfer to the
bed. One person should support their head throughout.
Approved restraint devices should be applied to the abdo-
men and upper and lower limbs.
Because some negative outcomes have been described
due to physical restraint, it is essential to closely supervise
the patient during the physical restraint including moni-
toring of general, clinical and safety variables. General
monitoring of physical restraint should include direct
observation of the patient each 15 min during the first
two hours and then hourly until the restraint is removed.
If IM medication was administered, monitoring should be
performed every 30 min during the first two hours, then
at four hours and at six hours. Monitoring should be
maintained for as long as the patient is restrained, and
for as long as the administration of the IM medication
lasts. Other assessments include the patient’s level of
consciousness. Changing the patient’s position every
hour and the holding devices should be repositioned to
reduce the risk of pressure sores and promote circulation
and the head of the bed must always be at a 30-degree
angle. Throughout the period of restraint, the patient’s
basic needs must be met including feeding, hydration, hy-
giene, elimination, active-passive mobilisation, posture,
body alignment, physical and emotional well-being, keep-
ing privacy and frequent communication with the patient.
The restrained patient should be clinically assessed at fre-
quents periods with the goal of removing the restraints as
Fig. 3 Algorithm for physical restraint. Algorithm for the patient with psychomotor agitation requiring physical restraint
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soon as possible. Restraints should be removed gradually
with a clear explanation of the behaviour expected of the
patient and with at least two HCPs present.
Protocol 3: After an episode of psychomotor agitation
After resolution of an episode of PMA, it is advisable to
debrief what happened with the therapeutic team and
with the patient and their family. An adequate review of
how the initial identification and care approach, assessment
and treatment process unfolded can help the clinical team
to better understand what happened, to share comments
on relevant variables, to review the action taken and to ana-
lyse possible improvements for future episodes [28].
It is advisable to discuss the subjective experience of
the patient, what they experienced, and what their ideas
and feelings were during their care. The objective of this
intervention is to help them to be conscious of how they
process reality and their emotional state during the epi-
sode of PMA. This process may also help the patient to
identify ways to prevent new episodes and establish an
agreed treatment plan in which the patient can partici-
pate voluntarily [28]. It is also important to enable the
patient how to recognise the signs which predict episodes
of PMA. In this way, the patient would learn to ask for help
earlier if a new episode of agitation appears. It is also advis-
able to explain to the patient the role of pharmacotherapy
in the prevention of symptom escalation [29]. Benefits
of this ulterior intervention include the restoration of
the therapeutic relationship, decreasing the traumatic
nature of some events such as emergency IM injections
and decreasing the risk of new episodes of PMA [29]. A
strong therapeutic alliance between the patient and the
therapeutic team leads to improved long-term control
of episodes of PMA.
Strengths and limitations
The most relevant strengths of this protocol proposal in-
clude the development process and the agreement among
experts. For the development process, we systematically
reviewed the evidence (Jadad’s and PRISMA criteria) and
for the agreement among experts, we applied a formal
consensus method and collected experts’ opinions (semi
structured interviews and external reviews) to reach an
agreement for the clinical guidelines related to PMA in
adult patients with a primary psychiatric condition. It is
relevant to highlight the conducted process of adapting
scientific literature to the daily clinical practice in the form
of an updated standardized protocol, which is easy to
apply in the clinical setting and to replicate. The key limi-
tations of our study are that (i) the consensus methods
and convenience samples of current international clinical
guidelines [2] may interfere with the Spanish standardized
policies, and for extension, with other local regulations;
(ii) that there are currently no gold standards for guideline
ensuring trustworthy, implementable, and clinically rele-
vant recommendations and (iii) that this protocol would
only benefit the agitated patient if it is used and imple-
mented in the clinical practice.
Conclusions
PMA, a state of motor restlessness and mental tension,
requires timely recognition, appropriate initial assessment
and management to minimize anxiety for the patient and
reduce the risk for escalation to aggression and violence
that may be directed towards themselves or others. Proto-
cols and algorithms can assist HCPs to identify patients at
risk for PMA, achieve timely diagnosis and implement
minimally invasive management strategies to ensure patient
and staff safety and resolution of the episode. The protocols
and algorithms provided here facilitate this process and
provide a structure for the provision of environmental
containment and verbal de-escalation with guidance on
the appropriate selection and use of pharmacological
treatment (inhaled/oral) and seclusion and physical re-
straint if needed. This protocol represents the application
and local adaptation of international consensus guidelines
on the standard of care for psychiatric patients suspected
of or presenting with PMA within the Spanish healthcare
system [2]. Further adaptions may be required for applica-
tion of this protocol to other healthcare systems.
Implementation of the algorithms described here should
ensure that patients at risk for PMA are identified and
monitored, episodes of PMA are identified early in their
clinical course and that patients can be managed in the
least invasive and confrontational way possible, ensuring
their own safety and that of others around them. A period
of reflection following an episode of PMA can help to re-
establish the therapeutic bond between patients and staff
and help the patient to recognise their own triggers and
identify the early signs of an impending episode. Establish-
ing specialized teams in agitation and providing them with
continuing medical education on the identification of
agitation, patient management and therapeutic pharmaco-
logical alternatives might reduce the burden of PMA for
both the patient and the health system.
Regular review and endorsement of PMA protocols
and systematic assessment of their level of implementation
in the hospital, might have an important effect in reducing
the burden of PMA in patients, decrease the need for coer-
cive measures and hospitalizations and especially reinforce
patient-physician alliance.
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